SMMT enters the final week of September carrying a striking disconnect: the stock is up 30% in a month, yet short sellers have added to their positions by nearly 18% over the same period.
The analyst story is the most important development of recent weeks. Jefferies made the boldest call, upgrading from Hold to Buy on September 9 and lifting its target from $15 to $25 — a signal that at least one firm sees the rally as fundamentally earned rather than speculative. Bernstein moved in the same direction, upgrading from Underperform to Market Perform in late August with a revised target of $11.90. The upgrades sit alongside a consensus mean target near $21.57, implying roughly 26% upside from the current $17.12. Not everyone is convinced: HC Wainwright has reiterated Neutral three times since late July without moving its target, and that persistent caution from a specialist biotech house is worth noting. The analyst recommendation divergence factor scores in the 98th percentile — meaning the gap between bulls and bears on this name is wider than almost every other stock in the universe.
The positioning picture is the week's most interesting tension. Short interest has climbed to 5.5% of the free float, up around 18% over the past month — bears building into the rally, not chasing it down. The borrow market is not particularly stressed, though: cost to borrow is running at roughly 0.88%, up about 62% over the month but still classified as low in absolute terms. Availability sits near 102%, meaning roughly one share is available to borrow for every one already lent out — tight relative to the loose conditions of early September (when availability ran above 150%), but not a level that signals imminent squeeze pressure. The ORTEX short score holds at 77.3, a level consistent with meaningful bearish conviction, and the short score rank sits in just the 5th percentile — flagging that the short-side thesis is one of the more aggressive in its peer universe.
Options traders are not sounding alarms. The put/call ratio is running at 0.62, barely above its 20-day average of 0.59 and less than one standard deviation from the norm. That's a neutral to mildly call-heavy posture — not the defensive hedging you'd expect if the market genuinely feared a reversal after a 30% move. The 52-week low on the PCR was 0.42; the current level is closer to the bottom of the historical range than the top (1.21), suggesting call demand has been a feature of this rally.
The ownership structure is worth a pause. Co-CEOs Robert Duggan and Mahkam Zanganeh are the dominant force in this stock — Duggan holds nearly 72% of shares outstanding. In June, both co-CEOs made open-market purchases at $13.12, committing approximately $50 million each in discretionary buys, not under a 10b5-1 plan. COO and CFO Manmeet Soni also bought in the same window. Those purchases were made at prices well below the current level, and while the insider data is now over 90 days old, the pattern of coordinated C-suite buying from a concentrated-ownership structure carries weight. The Goldman Sachs Group and Millennium Management both showed up as meaningful new entrants or enlargers of positions in the most recent 13F cycle, though those filings reflect June 30 data.
On fundamentals, the valuation is pre-revenue biotech territory: negative earnings yield, negative EV/EBITDA, and a price-to-book near 147x — all reflecting a stock priced on pipeline optionality rather than current earnings. The bull case centres on the clinical progress of ivonescimab and the collaboration with GSK. Bears point to the small shifts in efficacy data over time and limited subgroup disclosures. Q3 results are pencilled in for October 20. The last two earnings events tell a mixed story: an August print was followed by a 3.7% one-day gain and a 15.9% five-day gain, while a July event triggered a 7.3% one-day drop and an 8.8% five-day decline.
What to watch next: with earnings less than a month away and short sellers rebuilding positions into a 30% monthly rally, the October 20 print will sharpen the debate between those who see the Jefferies upgrade as validated and those who view the move as already pricing in news that has yet to arrive.
See the live data behind this article on ORTEX.
Open SMMT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
